Shots:
PDUFA goal date set to access the BLA submission by Pfizer for its pentavalent meningococcal vaccine (covering 5 common serogroups, MenABCWY), is Oct 2023
This BLA is based on the results from the P-III trial evaluating the safety, tolerability & immunogenicity of MenABCWY vs Trumenba + Menveo in adolescent patients (aged 10-25yr, n=2,400) across the US & Europe
The MenABCWY is a combination of Pfizer’s licensed meningococcal vaccines, Trumenba & Nimenrix that is developed to protect against the meningococcal serogroups that is a lead cause in IMD
Ref: Businesswire | Image: Pfizer
Related News:- Pfizer Reports P-III Trial Results of Pentavalent Meningococcal Vaccine (MenABCWY) for Invasive Meningococcal Disease
